SCHEMBL5571970

SCHEMBL5571970

CCOC(=O)c1cn(-c2ccc(F)cc2F)c2cc(N3CCNCC3)c(F)nc2c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.44
KDM4E B2RXH2 6/20 0.44
HPGD P15428 5/20 0.44
HSD17B10 Q99714 5/20 0.44
LMNA P02545 4/20 0.44
HTT P42858 2/20 0.42
TSHR P16473 2/20 0.42
BRD4 O60885 1/20 0.42
CYP2J2 P51589 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CMA1 P23946 2/20 0.39
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KMT2A Q03164 1/20 0.37
ROCK2 O75116 1/20 0.37
CDK1 P06493 1/20 0.37
PRKACA P17612 1/20 0.37
CDK2 P24941 1/20 0.37
CSNK1D P48730 1/20 0.37
GSK3A P49840 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5571721 0.87 LMNA (0.58) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL6780213 0.86 ALDH1A1 (0.60) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL5868646 0.86 TSHR (0.42) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL4293888 0.83 ALDH1A1 (0.41) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL5571971 0.80 KMT2A (0.57) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL5568328 0.77 KMT2A (0.46) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL6780839 0.76 KDM4E (0.51) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL8128846 0.76 KDM4E (0.56) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL5258973 0.74 KMT2A (0.57) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL5416374 0.73 KMT2A (0.52) ALDH1A1KDM4EHPGDHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730154-B1 RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES CUMBRE IP VENTURES L P (US) 2012-10-17 EP disclosed
US-7247634-B2 Rifamycin derivatives effective against drug-resistant microbes CUMBRE PHARMACEUTICALS INC. (US) 2007-07-24 US disclosed
US-20050261262-A1 Rifamycin derivatives effective against drug-resistant microbes CUMBRE INC. (US) 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261262-A1 Rifamycin derivatives effective against drug-resistant microbes RIF1, MRPL37, AURKAIP1 ALDH1A1 1731/4885KDM4E 2995/4885HPGD 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.